BioCardia reports FY2024 net loss $7.9M, cash $2.4M; CardiAMP HF data to be presented at ACC March 30

BioCardia, Inc.

Net loss $7.9M vs $11.6M in 2023; net cash used in ops $8.0M vs $10.0M.
Revenue $58K vs $477K; R&D expense $4.4M (down from $7.7M); SG&A $3.7M (down from $4.4M).
CardiAMP HF trial results to be presented at ACC Late-Breaking Clinical Trials on March 30, 2025; data intended for FDA/PMDA registration.
Completed low-dose cohort of CardiALLO (BCDA-03); DSMB review Q2 2025. First commercial Morph DNA steerable introducers available.
Cash and cash equivalents $2.4M at year-end 2024.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.